Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Skavdis, Andreas"'
Autor:
Kosmas, Constantine E, Muñoz Estrella, Alba, Skavdis, Andreas, Peña Genao, Edilberto, Martinez, Ian, Guzman, Eliscer
Publikováno v:
Therapeutics and Clinical Risk Management
Proprotein convertase subtilisin kexin 9 (PCSK-9)-targeting therapy has arisen as a new line for the treatment of hyperlipidemia. Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of PCSK-9, leading to a redu
Autor:
Kosmas,Constantine E, Skavdis,Andreas, Sourlas,Andreas, Papakonstantinou,Evangelia J, Peña Genao,Edilberto, Echavarria Uceta,Rogers, Guzman,Eliscer
Publikováno v:
Clinical Pharmacology: Advances and Applications.
Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2S
Autor:
Kosmas CE; Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA., Skavdis A; School of Medicine, University of Athens, Athens, Greece., Sourlas A; School of Medicine, University of Crete, Heraklion, Greece., Papakonstantinou EJ; General Directorate of Public Health and Social Welfare, Attica Region, Athens, Greece., Peña Genao E; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Echavarria Uceta R; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Guzman E; Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Publikováno v:
Clinical pharmacology : advances and applications [Clin Pharmacol] 2020 Dec 11; Vol. 12, pp. 191-202. Date of Electronic Publication: 2020 Dec 11 (Print Publication: 2020).